Methamphetamine and HIV: Intertwined Epidemics Among MSM

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > Colfax > Slides

Methamphetamine and HIV: Intertwined Epidemics Among MSM

Slide Presentation
October 11, 2006
Grant Colfax, MD

Click on slide thumbnails to view full-sized image.

Download Grant Colfax's powerpoint slides

Slide 1.

Methamphetamine and HIV: Intertwined epidemics among MSM

Slide 1.

(cartoon)

Slide 2.

What's new?

Slide 3.

Methamphetamine

Slide 4.

DA Neurotransmission

Slide 5.

Methamphetamine use

Slide 6.

Methamphetamine use among MSM

Slide 7.

Methamphetamine use and HIV risk

Slide 8.

Methamphetamine and HIV risk

Slide 9.

Methamphetamine and HIV seroconversion

Slide 10.

How can methamphetamine use be independently associated with HIV infection?

Slide 11.

Methamphetamine users have altered brain metabolism

Slide 12.

Methamphetamine users are deficient in dopamine

Slide 13.

Depressed mood improves with treatment for meth dependence

Slide 14.

Meth skin

Slide 15.

Meth mouth

Slide 16.

Non-adherence due to methamphetamine use

Slide 17.

Methamphetamine use is associated with primary drug resistance

Slide 18.

Interventions for methamphetamine users

Slide 19.

Meth treatment histories among meth-using MSM

Slide 20.

Counseling for meth dependence is associated with reduced meth use

Slide 21.

Matrix intervention: Reported number of days of meth use in past 30 days

Slide 22.

Counseling interventions among methamphetamine-dependent MSM

Slide 23.

Risk behavior declines among MSM in meth behavioral interventions

Slide 24.

Contingency Management

Slide 25.

MSM in contingency management reduce risk

Slide 26.

Positive Reinforcement Opportunity Project

Slide 27.

Will a behavioral risk-reduction approach work among MSM?

Slide 28.

Behavioral interventions Challenges

Slide 29.

Pharmacologic treatment for methamphetamine users

Slide 30.

Treatment Considerations: DA Dysfunction

Slide 31.

Potential medications to treat methamphetamine use

Slide 32.

SFDPH: phase II study of bupropion among meth-dependent MSM

Slide 33.

The Dual Deficit Model of drug dependence

Slide 34.

Pharmacologic approaches to treating methamphetamine dependence

Slide 35.

Pharmacologic approaches...

Slide 36.

Treatment Considerations: DA Dysfunction

Slide 37.

Pharmacologic interventions Challenges

Slide 38.

Conclusions

Slide 39.

Acknowledgements

Slide 40.